Thermocool Smarttouch News Today : Breaking News, Live Updates & Top Stories | Vimarsana

A platform with a mapping system and a large-tip catheter with dual pulsed field and radiofrequency energies was noninferior to a conventional radiofrequency ablation system for treatment of persistent atrial fibrillation, data show. For the SPHERE Per-AF noninferiority trial, presented at Heart Rhythm 2024 and simultaneously published in Nature Medicine, the researchers randomly assigned 420

Medtronic's SPHERE Per-AF study results reveal the Sphere-9 Catheter's superior safety and efficacy in treating persistent atrial fibrillation compared to the Thermocool SmartTouch SF. The Sphere-9 offers advanced mapping and ablation, showing higher freedom from AFib and fewer complications.

Medtronic (NYSE: MDT) announced data showing the safety and efficacy of its Affera mapping and ablation system with the Sphere-9 catheter.

Johnson & Johnson's Biosense Webster unit today announced positive three-month follow-up results from its SmartfIRE clinical trial.

Study will evaluate investigational Dual Energy Thermocool SmartTouch SF Catheter potential to deliver safe and effective radiofrequency (RF) and pulsed field ablation (PFA)